A genome‐wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells

Therapeutic resistance is a major clinical challenge in oncology. Evidence identifies cancer stem cells (CSCs) as a driver of tumor evolution. Accordingly, the key stemness property unique to CSCs may represent a reservoir of therapeutic target to improve cancer treatment. Here, we carried out a genome‐wide RNA interference screen to identify genes that regulate breast CSCs‐fate (bCSC). Using an interactome/regulome analysis, we integrated screen results in a functional mapping of the CSC‐related processes. This network analysis uncovered potential therapeutic targets controlling bCSC‐fate. We tested a panel of 15 compounds targeting these regulators. We showed that mifepristone, salinomycin, and JQ1 represent the best anti‐bCSC activity. A combination assay revealed a synergistic interaction of salinomycin/JQ1 association to deplete the bCSC population. Treatment of primary breast cancer xenografts with this combination reduced the tumor‐initiating cell population and limited metastatic development. The clinical relevance of our findings was reinforced by an association between the expression of the bCSC‐related networks and patient prognosis. Targeting bCSCs with salinomycin/JQ1 combination provides the basis for a new therapeutic approach in the treatment of breast cancer.

[1]  S. Conzen,et al.  Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer , 2013, Clinical Cancer Research.

[2]  Jae-seok Roe,et al.  BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements. , 2016, Cell reports.

[3]  Dennis Wang,et al.  Combenefit: an interactive platform for the analysis and visualization of drug combinations , 2016, Bioinform..

[4]  A. Krešo,et al.  Self-renewal as a therapeutic target in human colorectal cancer , 2013, Nature Medicine.

[5]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[6]  Elaine Fuchs,et al.  The Yin and Yang of Chromatin Dynamics In Stem Cell Fate Selection. , 2016, Trends in genetics : TIG.

[7]  J. Cheong,et al.  Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells , 2017, Autophagy.

[8]  Bert Gunter,et al.  Improved Statistical Methods for Hit Selection in High-Throughput Screening , 2003, Journal of biomolecular screening.

[9]  S. Armstrong,et al.  Mediator Kinase Inhibition Further Activates Super-Enhancer Associated Genes in AML , 2015, Nature.

[10]  Martin Vingron,et al.  Detection of interacting transcription factors in human tissues using predicted DNA binding affinity , 2012, BMC Genomics.

[11]  Joel s. Brown,et al.  Classifying the evolutionary and ecological features of neoplasms , 2017, Nature Reviews Cancer.

[12]  Stefano Piccolo,et al.  YAP/TAZ at the Roots of Cancer. , 2016, Cancer cell.

[13]  D. Birnbaum,et al.  Salinomycin kills cancer stem cells by sequestering iron in lysosomes , 2017, Nature Chemistry.

[14]  F. Bertucci,et al.  ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. , 2013, Cancer research.

[15]  S. Bicciato,et al.  Glucocorticoid receptor signalling activates YAP in breast cancer , 2017, Nature Communications.

[16]  R. Weinberg,et al.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications , 2017, Nature Reviews Clinical Oncology.

[17]  Pedro P. Rocha,et al.  MED12 Regulates HSC-Specific Enhancers Independently of Mediator Kinase Activity to Control Hematopoiesis. , 2016, Cell stem cell.

[18]  J. Jonkers,et al.  Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression. , 2015, Cell reports.

[19]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[20]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[21]  G. Bidaut,et al.  HTS-Net: An integrated regulome-interactome approach for establishing network regulation models in high-throughput screenings , 2017, PloS one.

[22]  for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005 .

[23]  James E. Bradner,et al.  Response and resistance to BET bromodomain inhibitors in triple negative breast cancer , 2015, Nature.

[24]  Benjamin G. Bitler,et al.  BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer. , 2016, Cancer research.

[25]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[26]  F. Bertucci,et al.  The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression , 2013, Clinical Cancer Research.

[27]  A. Krešo,et al.  Evolution of the cancer stem cell model. , 2014, Cell stem cell.

[28]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[29]  C. Bauvy,et al.  Inhibition of the autophagic flux by salinomycin in breast cancer stem-like/progenitor cells interferes with their maintenance , 2013, Autophagy.

[30]  H. Clevers,et al.  Cancer stem cells revisited , 2017, Nature Medicine.

[31]  D. Birnbaum,et al.  CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. , 2010, The Journal of clinical investigation.

[32]  Mel Greaves,et al.  Evolutionary determinants of cancer. , 2015, Cancer discovery.

[33]  R A Knight,et al.  DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information , 2014, Cell Death and Disease.

[34]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[35]  H. A. Rogoff,et al.  Suppression of cancer relapse and metastasis by inhibiting cancer stemness , 2015, Proceedings of the National Academy of Sciences.

[36]  G. Pruneri,et al.  Pre‐clinical validation of a selective anti‐cancer stem cell therapy for Numb‐deficient human breast cancers , 2017, EMBO molecular medicine.

[37]  J. Kaiser.  The cancer stem cell gamble. , 2015, Science.

[38]  F. Bertucci,et al.  miR-600 Acts as a Bimodal Switch that Regulates Breast Cancer Stem Cell Fate through WNT Signaling. , 2017, Cell reports.

[39]  Qingfei Jiang,et al.  RNA rewriting, recoding, and rewiring in human disease. , 2015, Trends in molecular medicine.

[40]  R. Margueron,et al.  The Multiple Facets of PRC2 Alterations in Cancers. , 2017, Journal of molecular biology.

[41]  Hans Clevers,et al.  The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. , 2011, Cell stem cell.

[42]  Maurizio Pellecchia,et al.  ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis. , 2016, Cell stem cell.

[43]  Jessica M. Rusert,et al.  ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia , 2012, Proceedings of the National Academy of Sciences.

[44]  T. Mukohara,et al.  Mediator Subunits MED1 and MED24 Cooperatively Contribute to Pubertal Mammary Gland Development and Growth of Breast Carcinoma Cells , 2012, Molecular and Cellular Biology.